SCHEMBL249465

SCHEMBL249465

COC(=O)C=Cc1ccc(F)cc1C[C@H]1C2CCC(O2)[C@@H]1C(=O)O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.40
GAA P10253 1/20 0.39
TFPI2 P48307 3/20 0.38
PPP1CA P62136 1/20 0.38
KDM4E B2RXH2 4/20 0.37
PPM1B O75688 2/20 0.36
PTPN1 P18031 1/20 0.36
PPP1CC P36873 1/20 0.36
ALDH1A1 P00352 3/20 0.36
MAPT P10636 2/20 0.36
MEN1 O00255 1/20 0.36
TP53 P04637 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36
HPGD P15428 1/20 0.36
ALOX15 P16050 1/20 0.36
CYP2C19 P33261 1/20 0.36
KMT2A Q03164 1/20 0.36
HSD17B10 Q99714 1/20 0.36
SLC6A4 P31645 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL249464 1.00 LMNA (0.40) LMNAGAATFPI2PPP1CAKDM4E
SCHEMBL250296 0.83 LMNA (0.43) LMNAGAATFPI2PPP1CAKDM4E
SCHEMBL250295 0.83 LMNA (0.43) LMNAGAATFPI2PPP1CAKDM4E
SCHEMBL14321976 0.78 PLG (0.33)
SCHEMBL250155 0.78 LMNA (0.41) LMNAGAATFPI2PPP1CAKDM4E
SCHEMBL19791029 0.76 ENPP2 (0.33) LMNAKDM4EALDH1A1MAPTMEN1
SCHEMBL868794 0.76 TBXA2R (0.36)
SCHEMBL250371 0.76 LMNA (0.45) LMNAGAATFPI2PPP1CAKDM4E
SCHEMBL250372 0.76 LMNA (0.45) LMNAGAATFPI2PPP1CAKDM4E
SCHEMBL14059090 0.76 TBXA2R (0.37)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2588196-B1 INHIBITION OF INFLAMMATION BYSIMULTANEOUS BLOCKADE OF MULTIPLE PROSTANOID RECEPTORS ALLERGAN INC (US) 2018-01-24 EP disclosed
US-8901159-B2 Inhibition of inflammation by simultaneous blockade of multiple prostanoid receptors ALLERGAN, INC. (US) 2014-12-02 US disclosed
US-20140187596-A1 FATTY ACID AMIDE HYDROLASE INHIHIBITORS FOR TREATING PAIN ALLERGAN, INC. (US) 2014-07-03 US disclosed
EP-2588196-A2 INHIBITION OF INFLAMMATION BYSIMULTANEOUS BLOCKADE OF MULTIPLE PROSTANOID RECEPTORS Allergan, Inc. (US) 2013-05-08 EP disclosed
US-20120329843-A1 FATTY ACID AMIDE HYDROLASE INHIHIBITORS FOR TREATING PAIN ALLERGAN, INC. 2012-12-27 US disclosed
WO-2012162416-A1 FATTY ACID AMIDE HYDROLASE INHIBITORS FOR TREATING PAIN ALLERGAN, INC. (US) 2012-11-29 WO disclosed
US-20120077857-A1 INHIBITION OF INFLAMMATION BYSIMULTANEOUS BLOCKADE OF MULTIPLE PROSTANOID RECEPTORS ALLERGAN, INC. (US) 2012-03-29 US disclosed
WO-2012003477-A2 INHIBITION OF INFLAMMATION BYSIMULTANEOUS BLOCKADE OF MULTIPLE PROSTANOID RECEPTORS ALLERGAN, INC. (US) 2012-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120329843-A1 FATTY ACID AMIDE HYDROLASE INHIHIBITORS FOR TREATING PAIN FAAH, FAAH2, HRH2 LMNA 3940/4885GAA 4284/4885TFPI2 1274/4885
US-20140187596-A1 FATTY ACID AMIDE HYDROLASE INHIHIBITORS FOR TREATING PAIN FAAH, FAAH2, HRH2 LMNA 3940/4885GAA 4284/4885TFPI2 1274/4885
US-20120077857-A1 INHIBITION OF INFLAMMATION BYSIMULTANEOUS BLOCKADE OF MULTIPLE PROSTANOID RECEPTORS LTB4R2, LTB4R, PTGIR LMNA 1321/4885GAA 4814/4885TFPI2 737/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.